secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001193125-24-248137
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal posts Q3 2024 Rezdiffra net sales of $62.2M; commercial coverage exceeds 80%
--------------------------------------------------------------------------------

- Third-quarter 2024 net sales of Rezdiffra $62.2M; no product revenue in prior year.
- Cash, equivalents, and marketable securities $1.0B at Sep 30, 2024.
- Operating expenses $178.5M vs $98.5M YoY; SG&A $107.6M driven by commercial launch.
- Commercial coverage achieved for >80% of lives; <5% require biopsy for diagnosis.
- Completed enrollment in MAESTRO-NASH OUTCOMES trial for compensated NASH cirrhosis; EMA decision mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524248137/0001193125-24-248137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524248137/d788088d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-248137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer